GlassScriptPhysician profile
James L Wells
NPI 1164509873
$1,501.78
in general payments reported to CMS, 2019-2025
22 companies · $507 in 2025
The $507 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $243 · 2020: $17.07 · 2021: $11.92 · 2023: $178 · 2024: $544 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,229.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $392.96 | 2023-2025 | |
| Genentech USA, INC. | $187.37 | 2019-2024 | Venclexta |
| Abbvie INC. | $130.42 | 2023-2025 | Ozurdex |
| Celgene Corporation | $99.13 | 2023-2024 | Reblozyl, Opdualag |
| Daiichi Sankyo INC. | $68.01 | 2025 | Datroway, Enhertu |
| Janssen Biotech, INC. | $66.08 | 2024-2025 | Tecvayli, Talvey, Darzalex |
| Genzyme Corporation | $59.15 | 2019-2023 | |
| Springworks Therapeutics, INC. | $54.55 | 2024-2025 | Ogsiveo |
| Pfizer INC. | $50.13 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $43.45 | 2024-2025 | Opdivo |
| Beigene USA, INC. | $41.15 | 2024 | Brukinsa |
| Array Biopharma INC | $41.02 | 2024-2025 | Mektovi, Braftovi, Tukysa |
| Gilead Sciences, INC. | $40.11 | 2021-2024 | |
| Exelixis INC. | $37.06 | 2019 | |
| Glaxosmithkline, LLC. | $36.10 | 2025 | Ojjaara |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $30.45 | 2020-2024 | Lynparza |
| Eisai INC. | $25.63 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $21.89 | 2024 | Libtayo |
| Accord Healthcare, INC. | $21.42 | 2024 | |
| Merck Sharp & Dohme LLC | $19.63 | 2019 | |
| Adc Therapeutics America, INC. | $19.37 | 2025 | |
| Tempus Ai, INC | $16.70 | 2025 | Xt Cdx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Wells listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.